Positron and computed tomography dual-scan - PET CT
Positron emission tomography-computed tomography (PET-CT), or simply "positron scan," combines positron emission tomography and computed tomography techniques to detect early-stage cancerous lesions, assess the size, distribution, activity, and spread of cancer cells. It can also be applied to neurological diseases such as primary brain tumors, Alzheimer's disease, and epilepsy.
Positron emission tomography (PET) scans can reveal changes in cellular metabolism. Because cancer cells absorb more glucose than normal cells, medical staff inject patients with a radioactive isotope drug called fluorodeoxyglucose (FDG) before the examination. The PET receiver detects the radiation-induced image, revealing cells that have absorbed more FDG. On the other hand, CT scans use X-rays to capture and collect data on body structures from different angles, producing high-resolution images. Therefore, combining the signals and images from PET and CT scans helps doctors accurately determine the location and condition of lesions.
Positron emission tomography (PET) scanning is suitable for most tumors because it has extremely high sensitivity to cellular metabolism, thus effectively identifying early-stage cancerous lesions and is widely used in cancer diagnosis.
Find out where the cancer is
- Determining the stage of cancer
- Determine if the tumor has spread
- Assist doctors in planning patient treatment plans, such as radiation therapy and chemotherapy.
- Evaluate treatment effectiveness
- Monitor for signs of recurrence
Related Articles
New options for targeted therapy for prostate cancer: Isotope therapy Lu-177 has a disease control rate of about 70%
Clinical treatment found that in metastatic castration-resistant prostate cancer (mC
The curative effect of advanced lung cancer lasted for more than 4 years! The targeted drug larotinib Vitrativi has strong anti-tumor activity
The cause of TRK fusion tumors is that one NTRK gene is incompatible with the other.
Hong Kong's first stereo positioning radiation therapy + immunotherapy combination therapy, a new hope for liver cancer patients
Primary liver cancer is one of the common malignant tumors in our country, most of which are asymptomatic.
Immunotherapy for lung cancer has added another reggie! Libtayo combination therapy is expected to become a first-line new solution
Immunotherapy for lung cancer has added another reggie! Libtayo combination therapy is expected to be successful
Doctor Updates
Cancer patients are prone to severe sequelae of snakes｜ Early vaccination reduces risk-Professional analysis by Dr. Li Yu Chung, Jacky
Cancer patients have reduced immunity and are prone to snakes. Symptoms include neuralgia and blisters, which are easily confused with cancer pain. Dr. Li Yu Chung, Jacky recommends that a new generation of recombinant snake vaccine be vaccinated before chemotherapy. Non-live vaccines are safer, with a protection rate of 87.7% and a protection period of 11 years. Taking antiviral drugs within 72 hours of the onset of the disease can reduce symptoms. The United Cancer Centre of Hong Kong provides vaccine consultation, vaccination and treatment services to help patients prevent cancer.
Yen Cheng-kuo passed away from lung adenocarcinoma | Dr. Li Yu Chung, Jacky analyzes 6 high-risk factors, survival rates, and the latest treatment options
Taiwanese male star Yan Zhengguo passed away from pulmonary adenocarcinoma, less than 1 year after his diagnosis. According to an analysis by Dr. Li Yu Chung, Jacky of the United Cancer Centre of Hong Kong, the fatal rate of lung cancer in Hong Kong is 66%, with 5,707 people diagnosed each year. Detailed description of 6 high-risk persons, 3 warning signs, 4 treatment options and survival rates. The treatment rate in the first phase is 90%, and early screening is the key. Provide targeted therapy, immunotherapy and LDCT lung cancer screening services.
Manulife Health Seminar, September 18, 2025: New Trends in the Treatment of Lung Cancer, Breast Cancer, and Prostate Cancer – Dr. Li Yu-chung of the Hong Kong United Oncology Centre shares his insights.
On September 18, 2025, Dr. Li Yu Chung, Jacky of the Department of Clinical Oncology at the Hong Kong United Oncology Centre (HKUOC) will share the latest treatment trends in lung cancer, breast cancer, and prostate cancer at the Manulife Health Seminar. The seminar will be held at Manulife Tower in Kwun Tong from 10:30 a.m. to 11:30 a.m. All are welcome to attend and learn about the cutting-edge treatment technologies and personalized plans!
Am730_genic test is so useful _ Help you take the right medicine to treat metastatic colorectal cancer
Am730_genic test is so useful _ Help you take the right medicine to treat metastatic colorectal cancer
【240711 Team Medicine Sharing Seminar】 New Trends in the treatment of lung cancer, breast cancer and prostate cancer
With advancements in medicine, cancer treatment has entered an era of precision and personalized care. Taking lung cancer, Hong Kong's leading cancer killer, as an example, next-generation sequencing technology can detect over 300 cancer genes at once, helping doctors screen and find the most appropriate treatment plan or clinical trial program. This not only avoids delaying treatment but also makes better use of limited resources to maximize benefits for patients.
【Medipartner * Medical Seminar】 New Trends in Lung Cancer Treatment and Nutritional Support
With advancements in medicine, cancer treatment has entered an era of precision and personalized care. Taking lung cancer, Hong Kong's leading cancer killer, as an example, next-generation sequencing technology can detect over 300 cancer genes at once, helping doctors screen and find the most appropriate treatment plan or clinical trial program. This not only avoids delaying treatment but also makes better use of limited resources to maximize benefits for patients.